MedTrace Logo

Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives

NCT04257045 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2024-07-12

No results posted yet for this study

Summary

This trial collects information about factors that affect communication of genetic test results, decision-making, and access to genetic testing in women with hereditary gynecological cancers. Studying individuals who are positive for a genetic mutation and immediate biological family members (including a parent, full-sibling, or child) may help identify cancer genes and other persons at risk.

Conditions

  • Breast Carcinoma
  • Deleterious CDH1 Gene Mutation
  • Deleterious DICER1 Gene Mutation
  • Deleterious SMARCA4 Gene Mutation
  • Deleterious STK11 Gene Mutation
  • Endometrial Carcinoma
  • Fallopian Tube Carcinoma
  • Ovarian Carcinoma
  • Primary Peritoneal Carcinoma

Interventions

OTHER

Interview

Participate in semi-structure, in-depth qualitative interviews

OTHER

Questionnaire Administration

Complete questionnaires

OTHER

Survey Administration

Complete survey

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Jose A Rauh-Hain · M.D. Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-21
Primary Completion
2024-07-09
Completion
2024-07-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04257045 on ClinicalTrials.gov